GBIO vs. ATOS, RIGL, ALIM, IXHL, OMER, LFCR, TELO, ELYM, GTHX, and VERU
Should you be buying Generation Bio stock or one of its competitors? The main competitors of Generation Bio include Atossa Therapeutics (ATOS), Rigel Pharmaceuticals (RIGL), Alimera Sciences (ALIM), Incannex Healthcare (IXHL), Omeros (OMER), Lifecore Biomedical (LFCR), Telomir Pharmaceuticals (TELO), Eliem Therapeutics (ELYM), G1 Therapeutics (GTHX), and Veru (VERU). These companies are all part of the "pharmaceutical preparations" industry.
Atossa Therapeutics (NASDAQ:ATOS) and Generation Bio (NASDAQ:GBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, community ranking, risk, analyst recommendations, earnings and institutional ownership.
12.7% of Atossa Therapeutics shares are owned by institutional investors. Comparatively, 95.2% of Generation Bio shares are owned by institutional investors. 7.8% of Atossa Therapeutics shares are owned by insiders. Comparatively, 21.1% of Generation Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, Atossa Therapeutics had 3 more articles in the media than Generation Bio. MarketBeat recorded 6 mentions for Atossa Therapeutics and 3 mentions for Generation Bio. Generation Bio's average media sentiment score of 0.97 beat Atossa Therapeutics' score of 0.00 indicating that Atossa Therapeutics is being referred to more favorably in the media.
Generation Bio's return on equity of -31.01% beat Atossa Therapeutics' return on equity.
Atossa Therapeutics currently has a consensus target price of $4.50, suggesting a potential upside of 202.01%. Generation Bio has a consensus target price of $8.00, suggesting a potential upside of 167.56%. Given Generation Bio's stronger consensus rating and higher probable upside, equities research analysts plainly believe Atossa Therapeutics is more favorable than Generation Bio.
Atossa Therapeutics has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, Generation Bio has a beta of 2.87, indicating that its stock price is 187% more volatile than the S&P 500.
Atossa Therapeutics received 192 more outperform votes than Generation Bio when rated by MarketBeat users. However, 66.67% of users gave Generation Bio an outperform vote while only 64.96% of users gave Atossa Therapeutics an outperform vote.
Atossa Therapeutics has higher earnings, but lower revenue than Generation Bio. Atossa Therapeutics is trading at a lower price-to-earnings ratio than Generation Bio, indicating that it is currently the more affordable of the two stocks.
Summary
Atossa Therapeutics beats Generation Bio on 9 of the 15 factors compared between the two stocks.
Get Generation Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Generation Bio Competitors List
Related Companies and Tools